Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Table 4

Multivariate Cox regression model for possible factors influencing OS of patients with metastatic breast cancer. Age was included as a continuous variable. ER/PR status was considered positive if either of the receptors was positive and negative if both were negative. Line of treatment variable compares patients receiving vinorelbine containing treatment as first line metastatic therapy and those receiving it as second or later line. Sites of metastases variable compares patients with bone metastases only and those with other sites also present (with or without bones).

Variable	Hazard ratio	95% confidence interval		𝑃 value
		Lower limit	Upper limit
Age	1.0275	1.0055	1.0499	0.014
ER/PR	1.1615	0.5982	2.2553	0.65
Trastuzumab	0.5032	0.2757	0.9183	0.025
Line of treatment	1.831	0.98	3.3891	0.053
Sites of metastases	1.1947	0.678	2.105	0.53